Takeda signs option deal for MacroGenics bi-specific antibody
This article was originally published in Scrip
Executive Summary
Takeda Pharmaceutical will pay MacroGenics $15m up front for an option to license the early-stage bi-specific antibody MGD010 for autoimmune diseases in an agreement worth up to $501.5m plus royalties.
You may also be interested in...
MacroGenics Regains DART Asset As Takeda Narrows Focus
MacroGenics has regained global rights to one of its DART compounds from Takeda, following a reprioritization of therapeutic areas by the Japanese firm that may open up new partnering opportunities in autoimmune disorders.
MacroGenics Signs Another Lucrative DART Deal with Janssen For $75m Up Front
Janssen Biotech Inc. apparently likes what it's seen so far from the first bi-specific antibody that it licensed from MacroGenics Inc., because the Johnson & Johnson subsidiary obtained rights to a second asset from the Rockville, Maryland-based firm's Dual Affinity Re-Targeting (DART) platform.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.